1. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
- Author
-
Lou, Si-yue, Zheng, Fan-li, Tang, Yong-mei, Zheng, Ya-nan, Lu, Jun, An, Hai, Zhang, En-jun, Cui, Sun-liang, and Zhao, Hua-jun
- Subjects
- *
B cells , *LYMPHOMAS , *ANTINEOPLASTIC agents , *HUMAN growth , *LABORATORY mice , *TUMOR growth , *B cell receptors - Abstract
PI3Kδ is expressed predominately in leukocytes and is commonly found to be aberrantly activated in human B-cell lymphomas. Although PI3Kδ has been intensively targeted for discovering anti-lymphoma drugs, the application of currently approved PI3Kδ inhibitors has been limited due to unwanted systemic toxicities, thus warranting the development of novel PI3Kδ inhibitors with new scaffolds. We designed TYM-3-98, an indazole derivative, and evaluated its selectivity for all four PI3K isoforms, as well as its efficacy against various B-cell lymphomas both in vitro and in vivo. We identified TYM-3-98 as a highly selective PI3Kδ inhibitor over other PI3K isoforms at both molecular and cellular levels. It showed superior antiproliferative activity in several B-lymphoma cell lines compared with the approved first-generation PI3Kδ inhibitor idelalisib. TYM-3-98 demonstrated a concentration-dependent PI3K/AKT/mTOR signaling blockage followed by apoptosis induction. In vivo , TYM-3-98 showed good pharmaceutical properties and remarkably reduced tumor growth in a human lymphoma xenograft model and a mouse lymphoma model. Our findings establish TYM-3-98 as a promising PI3Kδ inhibitor for the treatment of B-cell lymphoma. [Display omitted] • PI3Kδ is aberrantly activated in B-cell lymphomas which warrants novel inhibitors. • TYM-3-98 selectively inhibits the PI3Kδ/AKT signaling pathway and induces apoptosis in B-cell lymphomas. • TYM-3-98 suppresses the growth of B-cell lymphoma xenografts without showing evident hepatotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF